Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04030195 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
A Phase 1 study, sponsored by Precision BioSciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04030195 is a Phase 1 study that has completed, run by Precision BioSciences. The registered enrollment target is 18 participants.
The verdict
NCT04030195, a Phase 1 study, has completed, sponsored by Precision BioSciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r CLL/SLL.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- GENETIC PBCAR20A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-03-24 |
| Est. Completion | 2021-06-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04030195
The ClinicalTrials.gov registry entry for NCT04030195 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Precision BioSciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04030195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04030195 about?
NCT04030195 is a clinical study titled "Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL". This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r CLL/SLL.
What is the current status of trial NCT04030195?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-03-24. Estimated completion is 2021-06-24.
What interventions are being tested in trial NCT04030195?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), PBCAR20A (GENETIC).
Who is sponsoring clinical trial NCT04030195?
This trial is sponsored by Precision BioSciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.